National Cancer Institute; Amended Notice of Meeting, 4521-4522 [07-401]
Download as PDF
Federal Register / Vol. 72, No. 20 / Wednesday, January 31, 2007 / Notices
are to respond, including the use of
appropriate automated electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the Office of
Management and Budget, Office of
Regulatory Affairs, New Executive
Office Building, Room 10235,
Washington, DC 20503, Attention: Desk
Officer for NIH. To request more
information on the proposed project or
to obtain a copy of the data collection
plans and instruments, contact: Dr.
Nancy Breen, Ph.D., Project Officer,
Applied Research Program, Division of
Cancer Control and Population Sciences
NCI, NIH, EPN 4005, 6130 Executive
Boulevard MSC 7344. Bethesda,
Maryland 20852–7344, or call the nontoll-free number 301–696–8500 or Email your request, including your
address to breenn@mail.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30 days of the date of
this publication.
Dated: January 23, 2007.
Rachelle Ragland-Greene,
NCI Project Clearance Liaison, National
Institutes of Health.
[FR Doc. 07–406 Filed 1–30–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
mstockstill on PROD1PC62 with NOTICES
National Cancer Institute; Call for
Nominations for the National Cancer
Institute Director’s Consumer Liaison
Group
The National Cancer Institute (NCI)
the Federal Government’s primary
agency for cancer research, is seeking
nominations for four (4) new members
of the NCI Director’s Consumer Liaison
Group (DCLG) which will be appointed
in July, 2007. The DCLG helps NCI to
identify appropriate advocates to serve
on its program and policy advisory
committees.
The National Cancer Institute (NCI)
formed the NCI Director’s Consumer
Liaison Group (DCLG) in 1998 to advise
and make recommendations to the NCI
Director, from the perspective and
viewpoint of cancer consumer
advocates, on a wide variety of issues,
programs, and research priorities. The
VerDate Aug<31>2005
15:08 Jan 30, 2007
Jkt 211001
DCLG gives cancer advocates a channel
to voice their views and concerns. The
DCLG is a 16-member chartered federal
advisory committee that works with NCI
to ensure that those who experience the
burden of cancer also help to shape the
course of the NCI’s research to eradicate
it. Specifically the DCLG members:
• Help develop and establish
processes, mechanisms and criteria for
identifying appropriate consumer
advocates to serve on a variety of
program and policy advisory
committees responsible for advancing
the mission of the NCI.
• Serve as a primary forum for
discussion issues and concerns and
exchanging viewpoints that are
important to the broad development of
the NCI programming and research
priorities.
• Establish and maintain strong
collaborations between the NCI and the
cancer advocacy community to reach
common goals.
Eligibility Requirements: NCI looks for
strong, highly qualified candidates who
fulfill the following eligibility criteria:
• Demonstrate involvement in the
cancer experience as a cancer survivor,
a caregiver to someone who has cancer,
or as a professional or volunteer who
works with cancer survivors, patients,
or caregivers;
• Have a constituency with which
she/he regularly communicates on
cancer issues and with which she/he is
able to serve as a conduit for
information, both to and from NCI.
Nominees who meet the minimum
eligibility requirements will be
evaluated further based on the following
qualities:
• Cancer advocacy experience; ability
to represent all cancer survivors;
• Possession of strong leadership,
communication, and collaboration
skills;
• Ability to advise on broad cross
cutting cancer issues;
• Ability to facilitate dialogue
between NCI and the cancer advocacy
community.
DCLG members must be committed to
participating in all activities of the
DCLG which includes at least two
meetings a year in Bethesda, MD.
Characteristics of the DCLG. In
addition to the criteria for individual
candidates, the following characteristics
of the DCLG as a group are balanced to
ensure that it reflects the breadth and
diversity of the consumer advocacy
community:
• Racial and ethnic balance
• A broad mix of cancer sites
• Expertise with advocacy
organizations (local, regional, or
national)
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
4521
• Geographical diversity
• Gender
• Age diversity
Selection Process. A call for
nominations is disseminated annually
to a broad range of groups, including
local, regional and national
organizations, to encourage nominations
of candidates reflecting the diversity
sought for the DCLG. Individuals may
nominate themselves. All nominees are
screened for eligibility, and then
evaluated according to the criteria. A
list of highly qualified candidates who
reflect balance and diversity of
representation is forwarded to the
Director, NCI who selects the DCLG
members. The original members of the
DCLG endorsed this process and the
criteria developed to evaluate the
applications of potential DCLG
members, and this process is used to
select future members.
To receive a nomination package for
the DCLG, send your name, advocacy/
voluntary organization affiliation (if
any), address, phone number and E-mail
information to: Palladian Partners, Inc.,
Attn: DCLG 2007 Selection Process,
1010 Wayne Avenue, Suite 1200, Silver
Spring, MD 20910, Phone: (301) 650–
8660, Fax: (301) 650–8676.
Nominations must be postmarked by
March 30, 2007.
Dated: January 23, 2007.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy, National Institutes of
Health.
[FR Doc. 07–400 Filed 1–30–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Cancer
Institute Special Emphasis Panel,
February 27, 2007, 12 p.m. to February
27, 2007, 4 p.m., National Institutes of
Health, 6130 Executive Blvd., Rockville,
MD 20852 which was published in the
Federal Register on December 28, 2006,
71 FR 78214.
The meeting notice is changed to
reflect the change in the name of the
committee from ‘‘SBIR Topic 230
(Phases I & II)’’ to ‘‘SBIR, Synthesis
Stable Isotope-Labeled Steroids as
Internal Standards.’’ The meeting is
closed to the public.
E:\FR\FM\31JAN1.SGM
31JAN1
4522
Federal Register / Vol. 72, No. 20 / Wednesday, January 31, 2007 / Notices
Dated: January 23, 2007.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–401 Filed 1–30–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
mstockstill on PROD1PC62 with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Initial Review Group; Subcommittee
1—Career Development.
Date: February 27–28, 2007.
Time: 8 a.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Hilton Alexandria Old Town,
1767 King Street, Alexandria, VA 22314.
Contact Person: Robert Bird, PhD,
Scientific Review Administrator, Resources
and Training Review Branch, National
Cancer Institute, National Institutes of
Health, 6116 Executive Blvd., Room 8113,
MSC 8328, Bethesda, MD 20892–8328, 301–
496–7978, birdr@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Innovative
Technologies for Molecular Analysis of
Cancer.
Date: March 7–8, 2007.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott, 5151 Pooks Hill
Road, Bethesda, MD 20814.
Contact Person: Sherwood Githens, PhD,
Scientific Review Administrator, Special
Review and Logistics Branch, National
Cancer Institute, Division of Extramural
Activities, 6116 Executive Blvd., Room 8053,
Bethesda, MD 20892, 301–435–1822,
githenss@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, TW06–006
‘‘International Tobacco and Health Research
and Building Capacity.’’
Date: March 20–21, 2007.
VerDate Aug<31>2005
15:08 Jan 30, 2007
Jkt 211001
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Courtyard Gaithersburg
Washingtonian Center, 204 Boardwalk Place,
Gaithersburg, MD 20878.
Contact Person: Gerald G. Lovinger, PhD,
Scientific Review Administrator, Special
Review and Logistics Branch, Division of
Extramural Activities, National Cancer
Institute, 6116 Executive Blvd., Room 8101,
Bethesda, MD 20892–8329, 301–496–7987,
lovingeg@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: January 23, 2007.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–402 Filed 1–30–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Amended Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Heart, Lung,
and Blood Institute Special Emphasis
Panel, February 23, 2007, 8:30 a.m. to
February 23, 2007, 3 p.m., Embassy
Suites Hotel Washington Convention
Ctr., Washington, DC 20001 which was
published in the Federal Register on
January 12, 2007, FR 07–100.
The February 23, 2007 Meeting Panel
Name was changed from Modified
Hemoglobin Production to VAD
Technologies. The meeting is closed to
the public.
Dated: January 24, 2007.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–397 Filed 1–30–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Amended Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Heart, Lung,
and Blood Institute Special Emphasis
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
Panel, February 20, 2007, 2 p.m. to
February 20, 2007, 3 p.m., National
Institutes of Health, 6701 Rockledge
Drive, Bethesda, MD 20892 which was
published in the Federal Register on
January 12, 2007, FR 07–100.
The February 20, 2007 Meeting Panel
Name was changed from VAD
Technologies to Modified Hemoglobin
Production. The meeting is closed to the
public.
Dated: January 24, 2007.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–398 Filed 1–30–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Dental &
Craniofacial Research; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Dental and Craniofacial Research Special
Emphasis Panel; 07–43, Review R03, F30.
Date: February 12, 2007.
Time: 1:30 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, Bethesda,
MD 20892, (Telephone Conference Call).
Contact Person: Raj K. Krishnaraju, PhD,
MS, Scientific Review Administrator,
Scientific Review Branch, National Inst. of
Dental & Craniofacial Research, National
Institutes of Health, 45 Center Dr. Rm 4AN
32J, Bethesda, MD 20892, 301–594–4864,
kkrishna@nidcr.nih.gov.
Name of Committee: National Institute of
Dental and Craniofacial Research Special
Emphasis Panel; 07–35, Review R21.
Date: March 1, 2007.
Time: 11 a.m. to 12 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\31JAN1.SGM
31JAN1
Agencies
[Federal Register Volume 72, Number 20 (Wednesday, January 31, 2007)]
[Notices]
[Pages 4521-4522]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-401]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended Notice of Meeting
Notice is hereby given of a change in the meeting of the National
Cancer Institute Special Emphasis Panel, February 27, 2007, 12 p.m. to
February 27, 2007, 4 p.m., National Institutes of Health, 6130
Executive Blvd., Rockville, MD 20852 which was published in the Federal
Register on December 28, 2006, 71 FR 78214.
The meeting notice is changed to reflect the change in the name of
the committee from ``SBIR Topic 230 (Phases I & II)'' to ``SBIR,
Synthesis Stable Isotope-Labeled Steroids as Internal Standards.'' The
meeting is closed to the public.
[[Page 4522]]
Dated: January 23, 2007.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 07-401 Filed 1-30-07; 8:45 am]
BILLING CODE 4140-01-M